Standard versus reduced-dose chemoradiotherapy in anal cancer (PLATO-ACT4): short-term results of a phase 2 randomised controlled trialAlexandra Gilbert, Stephen A. Falk, Rob Glynne‐Jones et al.|The Lancet Oncology|2025Cited by 23
Multicentre Investigation of Prognostic Factors Incorporating p16 and Tumour Infiltrating Lymphocytes for Anal Cancer After ChemoradiotherapyKatie Wakeham, Duncan C. Gilbert, Louise Murray et al.|Clinical Oncology|2021Cited by 17
Personalising anal cancer radiotherapy dose (PLATO): protocol for a multicentre integrated platform trialRussell Frood, David Sebag‐Montefiore, Alexandra Gilbert et al.|BMJ Open|2025Cited by 8
Standard Versus Dose Reduced Chemoradiotherapy in Anal Cancer: Short Term Results of the PhaseII PLATO-ACT4 Randomised Controlled Trial (RCT) ISRCTN88455282Alexandra Gilbert, Mark Harrison, Richard Adams et al.|SSRN Electronic Journal|2025Cited by 3
3665 PLATO ACT 4: Long term results of an RCT evaluating reduced dose and standard dose chemoradiotherapy in early-stage anal cancer (ISRCTN:88455282)David Sebag‐Montefiore, Richard Adams, Mark Harrison et al.|Radiotherapy and Oncology|2025Cited by 1